Per Lennart Lindberg

Title: Per Lennart Lindberg: Innovator in Cancer Treatment

Introduction

Per Lennart Lindberg is a notable inventor based in Sweden. He has made significant contributions to the field of cancer treatment, particularly in the development of folate alternatives for chemotherapy. His work focuses on improving the efficacy of existing treatments for solid tumors, including colorectal cancer.

Latest Patents

Lindberg's latest patents include innovative methods for administering folate adjuvants in chemotherapy. One of his inventions, titled "[6R]-Mthf - An Efficient Folate Alternative In 5-Fluorouracil Based Chemotherapy," relates to the treatment of solid tumors in humans. This invention involves administering the diastereomerically pure folate adjuvant [6R]-5,10-methylenetetrahydrofolate in conjunction with 5-fluorouracil (5-FU) based chemotherapy. Another patent, "[6R]-Mthf Multiple Bolus Administration In 5-Fluorouracil Based Chemotherapy," also addresses the treatment of solid tumors, focusing on the administration of multiple boluses of the same folate adjuvant in 5-FU based chemotherapy.

Career Highlights

Lindberg is currently associated with Isofol Medical AB, a company dedicated to advancing cancer treatment through innovative therapies. His work has been instrumental in developing new approaches to enhance the effectiveness of chemotherapy for patients suffering from colorectal cancer.

Collaborations

Throughout his career, Lindberg has collaborated with esteemed colleagues, including Gunnel Elisabeth Sunden and Bengt Gustavsson. These partnerships have contributed to the advancement of research and development in the field of oncology.

Conclusion

Per Lennart Lindberg's contributions to cancer treatment through innovative patent developments highlight his commitment to improving patient outcomes. His work continues to influence the landscape of chemotherapy, particularly for colorectal cancer.